For relapsed or resistant DLBCL, odronextamab produced positive results.

Published Date: 22 Dec 2023

Experts are unsure of how it would fit in with the currently accepted bispecifics, though.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

2.

Why palliative care goes hand in hand with treatment for people with cancer: Q&A

3.

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

4.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

5.

Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot